DEFA14A: Surmodics Faces FTC Second Request, Merger Timeline Extended

Surmodics and BCE Parent, LLC receive a second request for information from the FTC, extending the waiting period for their merger, but still anticipate closing the deal by February 28, 2025.

Summary

• Surmodics, Inc. entered into a Merger Agreement with BCE Parent, LLC on May 28, 2024.
• On August 12, 2024, both Surmodics and BCE Parent received a second request from the FTC for additional information related to the merger.
• This Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) until 30 days after substantial compliance, unless terminated sooner by the FTC.
• Surmodics and Parent are cooperating with the FTC to expedite the HSR Act waiting period.
• The merger is still subject to the expiration or termination of the HSR Act waiting period and other customary closing conditions.
• The companies expect to complete the merger before the outside date of February 28, 2025, subject to possible extension.
• If the Merger Agreement is terminated under certain circumstances, the Company may be required to pay Parent a termination fee of $20,380,000.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the merger is still expected to proceed, the FTC's Second Request introduces uncertainty and potential delays. The risk factors outlined also contribute to a more cautious outlook.

Positives

• Surmodics and Parent are cooperating with the FTC to expedite the merger process.
• The companies still expect to consummate the merger prior to the ultimate outside date under the Merger Agreement.

Negatives

• The Second Request from the FTC extends the waiting period for the merger.
• The merger faces risks related to securing regulatory approvals and satisfying closing conditions.
• The company may be required to pay Parent a termination fee of $20,380,000 under certain circumstances.

Risks

• The merger may not be consummated within the anticipated time period, or at all.
• Shareholder approval of the Merger Agreement may not be obtained.
• The parties may fail to secure the termination or expiration of any waiting period applicable under the HSR Act.
• Other conditions to the consummation of the Merger under the Merger Agreement may not be satisfied.
• All or part of Parent's financing may not become available.
• Significant limitations on remedies contained in the Merger Agreement may limit or entirely prevent the Company from specifically enforcing Parent's obligations under the Merger Agreement or recovering damages for any breach by Parent.
• The Company's stock price may decline significantly if the Merger is not completed.
• The Merger Agreement may be terminated in circumstances requiring the Company to pay Parent a termination fee of $20,380,000.
• The circumstances of the termination may have a chilling effect on alternatives to the Merger.
• The Company's business, operating results or stock price may suffer as a result of the announcement or pendency of the Merger.
• The Company's current plans and operations may be disrupted.
• The Company's ability to retain or recruit key employees may be adversely affected.
• The Company's business relationships may be adversely affected.
• The Company's management's or employees' attention may be diverted from other important matters.
• The effect of limitations that the Merger Agreement places on the Company's ability to operate its business, return capital to shareholders or engage in alternative transactions.
• The nature, cost and outcome of pending and future litigation and other legal proceedings, including any such proceedings related to the Merger and instituted against the Company and others.
• The risk that the Merger and related transactions may involve unexpected costs, liabilities or delays.
• Other economic, business, competitive, legal, regulatory, and/or tax factors.

Future Outlook

The Company and Parent expect to consummate the Merger prior to the ultimate outside date under the Merger Agreement, which is currently February 28, 2025, subject to extension as provided in the Merger Agreement.

Industry Context

The request for additional information from the FTC suggests increased scrutiny of mergers and acquisitions in the medical technology sector, potentially indicating a trend towards stricter antitrust enforcement.

Stakeholder Impact

• Shareholders face uncertainty regarding the completion and timing of the merger.
• Employees may experience anxiety related to job security during the merger process.
• Customers and suppliers may be affected by potential changes in the company's operations following the merger.

Next Steps

• Surmodics and Parent will gather information and documentary materials responsive to the Second Request.
• The companies will continue to cooperate with the FTC to obtain expiration or termination of the HSR Act waiting period.
• The companies will work to satisfy other customary closing conditions.

Key Dates

Keywords

Merger, Surmodics, FTC, HSR Act, BCE Parent, Antitrust, Acquisition